Discriminant analysis of the metabolic effects of a new combined contraceptive vaginal ring containing Nestorone/EE vs. a second-generation oral contraceptive containing levonorgestrel/EE
Rad M et al. – Discriminant analysis (DA) identifies differences between combined hormonal contraceptives (CHC) and may provide information on the factors associated with thrombotic risk.Methods
- Data were used of a parallel study in premenopausal women treated for three cycles (21 days on, 7 days off) with a contraceptive vaginal ring delivering Nestorone and ethinyl estradiol (EE) or an oral contraceptive containing levonorgestrel and EE.
- DA was performed on the change from baseline (CFB) and the end–of–treatment values at 3 months for lipids, sex–hormone binding globulin (SHBG), C–reactive protein, angiotensinogen, blood pressure and hemostasis variables, and on the hemostasis variables only.
- For the complete set, the CFB for factor VII (FVII), SHBG and plasminogen (PLG), or end–of–treatment SHBG– and FVII level discriminated the treatments best.
- Maximal discrimination for the hemostasis data was by CFB for FVII and PLG or end–of–treatment FVII level.